التفاصيل البيبلوغرافية
| العنوان: |
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial |
| المؤلفون: |
Soumerai, Jacob D, Mato, Anthony R, Dogan, Ahmet, Seshan, Venkatraman E, Joffe, Erel, Flaherty, Kelsey, Carter, Jason, Hochberg, Ephraim, Barnes, Jeffrey A, Hamilton, Audrey M, Abramson, Jeremy S, Batlevi, Connie L, Matasar, Matthew J, Noy, Ariela, Owens, Colette N, Palomba, M Lia, Kumar, Anita, Takvorian, Tak, Ni, Ai, Choma, Morgan, Friedman, Chaya, Chadha, Puja, Simkins, Elizabeth, Ruiters, Jade, Sechio, Sidney, Portman, Daneal, Ramos, Lauren, Nolet, Natascha, Mahajan, Neena, Martignetti, Rosalba, Mi, Joanna, Scorsune, Krista, Lynch, Julia, McGree, Brianne, Hughes, Stephanie, Grieve, Clare, Roeker, Lindsey E, Thompson, Meghan, Johnson, P Connor, Roshal, Mikhail, Huang, Jane, Biondo, Juliana, Wu, Qun, Jacob, Allison, Abdel-Wahab, Omar, Zelenetz, Andrew D * |
| المصدر: |
In The Lancet Haematology December 2021 8(12):e879-e890 |
| قاعدة البيانات: |
ScienceDirect |
Full Text via ClinicalKey 
Full Text Finder